Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2009

View Archived Issues

ABI-200 developed as a topical antimicrobial alternative to mupirocin

Can-Fite BioPharma initiates preparation for phase III psoriasis trial of CF-101

MGN-1703 safe and well tolerated in phase I trial in subjects with metastatic malignancies

IMO-2055 combined with erlotinib/bevacizumab well tolerated in NSCLC patients

S/GSK-1265744 shows potent short-term antiviral efficacy in HIV-infected subjects

NAI-107 has potent in vitro/in vivo activity against multidrug-resistant Gram-positive pathogens

MBX-1684 potently inhibits the type III secretion system of P. aeruginosa in vitro

ACE-031 increases lean body mass and muscle volume in healthy postmenopausal women

Addrenex submits sNDA to FDA for Clonicel in ADHD

Hologic receives CE marking approval for ThinPrep integrated imager for cervical cancer screening

Response Genetics launches ResponseDX Gastric diagnostic test for gastric cancer

Advaxis reports results from phase I trial of ADXS11-001 vaccine in cervical cancer

Vifor reports results from phase III study of Ferinject in iron deficiency and CHF

FDA approves new indication of Bayer's Mirena for heavy menstrual bleeding

CHMP issues positive opinion for Baxter's Celvapan H1N1 pandemic influenza vaccine

FDA approves Oncolytics Biotech's SPA for phase III Reolysin trial in head and neck cancers

Medicago initiates phase I human clinical trial of avian influenza vaccine

FDA grants fast track designation to Corthera's relaxin for acute heart failure

ArQule presents update on clinical development of ARQ-197

SciClone discontinues phase II RP-101 trial in late-stage pancreatic cancer

Amicus Therapeutics reports results of phase II Plicera study for Gaucher disease

Seattle Genetics discontinues phase IIb dacetuzumab trial

Muscarinic M1 receptor allosteric modulators claimed by Merck & Co. for AD

Novel PPARgamma agonist for the treatment of diabetes described by Adamed

Histamine H1 receptor antagonists in early development at Nippon Zoki

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...